Decoy lymphotoxin  receptor (LTR) has potent immune inhibitory activities and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases, and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LT-LTR and LIGHT-HVEM/LTR, underlying molecular mechanisms have yet to be fully understood. In this study, we demonstrate that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models.
Anti-host cytotoxic T lymphocyte (CTL)activity
IntroductionThe functional network of tumor necrosis factor (TNF) and TNF receptor superfamily members is composed of complex cross-talk between multiple ligands and multiple receptors, which regulate pleiotropic functions in the immune system. 1 LIGHT, standing for homologous to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes, is a type II transmembrane glycoprotein belonging to the TNF ligand superfamily. 2 LIGHT is expressed on immature dendritic cells (DCs) and activated T cells 2,3 and interacts with 2 functional receptors, lymphotoxin- receptor (LTR) and HVEM. 2 LIGHT interaction with LTR triggers the production of proinflammatory mediators, 4,5 up-regulates adhesion molecule expression, 6 and induces apoptotic cell death in certain tumors. 7 On the other hand, by signaling through HVEM, LIGHT costimulates T-cell activation. 8 In vivo experiments demonstrated that transgenic expression of LIGHT leads to spontaneous progression of inflammatory autoimmunity such as Crohn disease, 9-11 while genetic disruption of LIGHT results in impaired T-cell activation, particularly in CD8 ϩ T cells, [12][13][14][15] and renders mice less vulnerable to pathogenic inflammation, as shown in acute hepatitis models. 16 Thus, LIGHT regulates multiple immune functions of innate and adaptive immunity through interactions with LTR and HVEM.There are numerous reports demonstrating therapeutic effects of decoy protein of LTR in various immunologic diseases, including autoimmunity, inflammation, and transplantation, 17,18 indicating that decoy LTR could be a potential biologic for clinical immunotherapy, analogous to a decoy form of TNF-receptor. 19 Prolonged administration of decoy LTR, however, might become a double-edged sword since it abrogates the maintenance of DC and natural killer/natural killer T (NK/NKT) cells 20,21 and inhibits the microstructure formation of lymphoid organs, 22 thus disrupting immune homeostasis. Therefore, it is of great interest to discover novel approaches that separate the therapeutic effects of decoy LTR from the potential adverse effects. While decoy LTR interferes with 3 molecular interactions-LT-LTR, LIGHT-LTR, and LIGHT-HVEM-the antihomeostatic effects are largely dependent on LT-LTR functions since the corresponding phenotypes are observed in LT-or LTR-KO mice but not in LIGHT-KO mice. [12][13][14][15][23][2...